Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Cash & Equivalents (2022 - 2026)

Cannabis Bioscience International Holdings' Cash & Equivalents history spans 5 years, with the latest figure at $90.0 for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 83.58% to $90.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $90.0, a 83.58% decrease, with the full-year FY2025 number at $12952.0, up 1615.5% from a year prior.
  • Cash & Equivalents hit $90.0 in Q1 2026 for Cannabis Bioscience International Holdings, down from $132.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for CBIH hit a ceiling of $25655.0 in Q1 2023 and a floor of $90.0 in Q1 2026.
  • Historically, Cash & Equivalents has averaged $5800.4 across 5 years, with a median of $881.5 in 2024.
  • Biggest five-year swings in Cash & Equivalents: plummeted 98.6% in 2023 and later surged 1615.5% in 2025.
  • Tracing CBIH's Cash & Equivalents over 5 years: stood at $24089.0 in 2022, then tumbled by 98.6% to $337.0 in 2023, then surged by 197.33% to $1002.0 in 2024, then tumbled by 86.83% to $132.0 in 2025, then plummeted by 31.82% to $90.0 in 2026.
  • Business Quant data shows Cash & Equivalents for CBIH at $90.0 in Q1 2026, $132.0 in Q4 2025, and $223.0 in Q3 2025.